NRD
INSM icon

Nebula Research & Development’s Insmed INSM Stock Holding History

Nebula Research & Development’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,661
Closed -$3.69M – 427
2025
Q2 		$3.69M Buy
36,661
+33,282
+985% +$2.54M 0.31% 58
2025
Q1 		$258K Buy
+3,379
New +$258K 0.02% 800
2024
Q4 		– Sell
-18,636
Closed -$1.36M – 998
2024
Q3 		$1.36M Buy
+18,636
New +$1.38M 0.16% 199
2023
Q4 		– Sell
-27,867
Closed -$704K – 756
2023
Q3 		$704K Buy
+27,867
New +$637K 0.37% 59

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nebula Research & Development's INSM Position: Q3 2025 in Review

Nebula Research & Development sold out of Insmed (INSM) in Q3 2025, closing a stake of 36,661 shares — an estimated $3.69M sold.

Nebula Research & Development first reported a position in INSM in Q3 2023 and held it in 4 quarters. The position peaked at $3.69M in Q2 2025. 566 funds tracked by Wall St. Rank hold INSM as of Q3 2025.

  • Nebula Research & Development reported no remaining Insmed position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 36,661 Insmed shares in Q3 2025, an estimated $3.69M.
  • Nebula Research & Development first reported a position in Insmed in Q3 2023 and held it in 4 quarters.
  • Nebula Research & Development's Insmed position peaked at $3.69M in Q2 2025.
  • 566 funds tracked by Wall St. Rank held Insmed as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.